Short-term anti-CD3 stimulation of lymphocytes to increase their in vivo acitivity

US5316763A · kind A · utility

Assignees

• The United States of America, as represented by the Department of Health and Human Services · US
• Regents of the University of Minnesota · US

Inventors

• Augusto C. Ochoa · Windom, US
• Cynthia Loeffler · Bladensburg, US
• Walter Urba · Gaithersburg, US
• Dan L. Longo · Kensington, US

Key dates

• Filing date: Jul 10, 1992
• Grant date: May 31, 1994
• Expiry date: Jul 10, 2012

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2501/515
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is directed to a method of increasing the in vivo immune response of lymphocytes by stimulating the lymphocytes in vitro in the presence of an anti-CD3 monoclonal antibody for less than about 24 hours to form stimulated lymphocytes; infusing the stimulated lymphocytes into a tumor-bearing mammal; and administering IL-2 to the mammal. As a result of this method, the anti-CD3 stimulated lymphocytes display enhanced immunotherapeutic, e.g., cytotoxicity or lymphokine production, in vivo as represented by a decrease in the number of tumors by at least about 20%.